类风湿关节炎患者由利妥昔单抗转换为生物类似药CT-P10的72周随机III期试验数据
该跨国随机双盲III期试验评估了类风湿关节炎患者从利妥昔单抗(US-RTX或EU-RTX)转换为CT-P10后的疗效与安全性。72周数据显示,各治疗组在DAS28、ACR应答率及生活质量改善方面相似,转换未导致临床意义差异,免疫原性与安全性特征相当。
要点
- 转换至CT-P10后72周疗效与持续使用参照药或CT-P10者相似。
- 转换未增加免疫原性风险,仅2例新发抗药抗体。
- 各治疗组药效学与安全性特征无临床意义差异。
核心结论
- CT-P10长期使用至72周有效且耐受良好,从参照利妥昔单抗转换为CT-P10未导致疗效、药效学、免疫原性和安全性的临床意义差异。
研究设计与样本
- 跨国、随机、双盲III期试验,患者先接受48周CT-P10或美国/欧盟来源参照利妥昔单抗治疗,进入48-72周扩展期后分为CT-P10/CT-P10组(n=122)、US-RTX/US-RTX组(n=64)、US-RTX/CT-P10组(n=62)和EU-RTX/CT-P10组(n=47)。
主要发现
- 第72周时,四个扩展期治疗组在DAS28和ACR应答率等疾病活动参数上均显示相似改善。
- 所有组在第72周相对于基线的生活质量改善相似。
- 扩展期研究药物输注后,2例患者检测到新发抗药抗体。
- 各组药效学与安全性特征相似。
关键数值与推荐
- 疗效终点包括DAS28、ACR应答率和生活质量相关参数;第72周时四组DAS28和ACR应答率相似。
- 免疫原性:扩展期输注后2例患者新发抗药抗体。
临床怎么用
- 对于接受参照利妥昔单抗治疗的RA患者,转换为CT-P10在72周内疗效与安全性可接受,未观察到临床意义差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of CT-P10, a rituximab biosimilar after a single switch, during a multinational, randomized, double-blind Phase 3 trial involving patients with RA. METHODS: Patients received 48 weeks' treatment with CT-P10 or United States- or European Union-sourced reference rituximab (US-RTX and EU-RTX, respectively). Patients entering the extension period (weeks 48-72) remained on CT-P10 (CT-P10/CT-P10; n = 122) or US-RTX (US-RTX/US-RTX; n = 64), or switched to CT-P10 from US-RTX (US-RTX/CT-P10; n = 62) or EU-RTX (EU-RTX/CT-P10; n = 47) for an additional course. Efficacy endpoints included Disease Activity Score using 28 joints (DAS28), American College of Rheumatology (ACR) response rates, and quality of life-related parameters. Pharmacodynamics, immunogenicity and safety were also assessed. RESULTS: At week 72, similar improvements were observed by disease activity parameters including DAS28 and ACR response rate in the four extension period treatment groups. Quality of life improvements at week 72 vs baseline were similarly shown during the extension period in all groups. Newly developed anti-drug antibodies were detected in two patients following study drug infusion in the extension period. Similar pharmacodynamic and safety profiles were observed across groups. CONCLUSION: Long-term use of CT-P10 up to 72 weeks was effective and well tolerated. Furthermore, switching from reference rituximab to CT-P10 in RA was well tolerated and did not result in any clinically meaningful differences in terms of efficacy, pharmacodynamics, immunogenicity and safety. TRAIL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT02149121.
引用
- Shim SC, Božić-Majstorović L, Berrocal Kasay A, et al. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. Rheumatology (Oxford). 2019. PMID: 31184752. doi:10.1093/rheumatology/kez152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。